NabGen has developed a co-therapy designed to overcome pre-existing immunity and re-administration barriers of gene therapies based on adeno-associated virus (AAV) vectors.
Company Details
Company type
Year founded
2019
Employment range in NC
US headquarters
North Carolina
Global headquarters
United States
Primary site activity
All company activities
Potential end market(s)